Special Issue

New Pharmacologic Approaches to Study and Intervene in Epithelial to Mesenchymal Transition (EMT) and Fibrosis

Message from the Guest Editors

Fibrosis is a general mechanism of response to a wide range of insults and is characterized by abnormal production and remodeling of extracellular matrix proteins. This process is regulated by a number of extracellular mediators and deeply impacts cell behavior through changes in mechanosensing, cellular plasticity and cell-to cell communication.

Importantly, due to the incomplete ability of endogenous mechanisms to remove the fibrotic deposits, and since no resolutive therapies are available to date, the persistence of profibrotic conditions may cause scarring and thickening of the affected tissue with persistent organ damage and loss of function.

The journal Pharmaceuticals invites both reviews and original articles shedding light on the challenges and opportunities of pharmacological treatment of every aspect of fibrosis. Topics include rational of pharmacological treatment for EMT-MET dynamics, control of fibrosis by autophagy, oxidative response, hypoxia, epigenetic mechanisms, new drugs, and new methods of pharmacological delivery, including nanomedicine.

Guest Editors

Dr. Raffaele Strippoli

Dr. Marco Cordani

Dr. Sergio Valente

Dr. Marco Tafani

Deadline for manuscript submissions

closed (31 March 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/56340

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

